Rankings
▼
Calendar
RCUS Q1 2024 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena
RCUS
Arcus Biosciences, Inc.
$2B
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$145M
+480.0% YoY
Gross Profit
$145M
100.0% margin
Operating Income
-$16M
-11.0% margin
Net Income
-$4M
-2.8% margin
EPS (Diluted)
$-0.05
QoQ Revenue Growth
+367.7%
Cash Flow
Operating Cash Flow
-$2M
Free Cash Flow
-$6M
Stock-Based Comp.
$20M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$586M
Stockholders' Equity
$707M
Cash & Equivalents
$185M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$145M
$25M
+480.0%
Gross Profit
$145M
$25M
+480.0%
Operating Income
-$16M
-$86M
+81.4%
Net Income
-$4M
-$80M
+95.0%
Revenue Segments
License and Development Services Revenue
$135M
93%
Other Collaboration Revenue
$10M
7%
← FY 2024
All Quarters
Q2 2024 →